{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-157864","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.819598+00:00","generated_at":"2026-06-14T10:10:41.933396+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon announces proposed public offering and concurrent private placement to fund INPEFA launch","bullets":["FDA approved INPEFA (sotagliflozin) on May 26, 2023 for heart failure and type 2 diabetes with CKD.","Company expects commercial availability by end of June; sales team booked over 5,000 appointments.","Proposed underwritten public offering of common stock; concurrent private placement to Invus affiliate.","Net proceeds to fund commercial launch of INPEFA, R&D, and working capital.","Bookrunners: Citigroup, Jefferies, Piper Sandler; 30-day over-allotment option to underwriters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-157864","json":"https://secwatch.observer/filing/0001193125-23-157864.json","markdown":"https://secwatch.observer/filing/0001193125-23-157864.md","text":"https://secwatch.observer/filing/0001193125-23-157864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/0001193125-23-157864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/d507509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:10:41.933396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}